2023-07-04 09:58:48
pharmaceutical organization Signed a Memorandum of Understanding for SK bioscience Co., Ltd., Republic of Korea, to produce influenza vaccine from cell cultures in Thailand. It is expected that next year the vaccine will be ready to be packaged. Phase 2 will receive technology transfer from upstream to downstream. Ready to expand the production of other vaccines such as shingles prevention
On July 4, at the Ministry of Public Health (Sor Sor.) Dr. Opas Karnkawinpong Permanent Secretary of the Ministry of Public Health (Sor.Phor.) Presided over the signing of a memorandum of understanding between Dr. Mingkwan Suphanpong, Director of the Pharmaceutical Organization (GPO) and Mr. An Jae Yong, Chief Executive Officer, SK Bioscience Company Limited, Republic of Korea. with Mr. Jon Jo Young, Chargé d’affaires, Royal Thai Embassy Republic of Korea in Thailand witness
Thailand and Korea move forward in vaccine production
Dr. Opas said that Thailand attended a ratification ceremony with the International Vaccine Institute (IVI) in Seoul, Republic of Korea on October 25, 2022 to mobilize international cooperation in shaping the future of vaccines for the country’s public health security. which the development of vaccine technology resulting in more effective treatment of the disease Vaccine personnel must constantly adapt and learn technology. to deal with changes in a timely manner This MOU paves the way for the sharing of knowledge and expertise of the two countries. with the same goal To strengthen the health systems of both countries to be stable. Including improving the quality of life of people to have better access to vaccines that are important to health.
Government Pharmaceutical Organization Vaccine Factory Ready to join Korea in the production of influenza vaccines
Dr. Mingkwan said that the vaccine factory of the Ministry of Public Health has researched and developed the production of influenza vaccines in the event of an outbreak and seasonality. until success And from the COVID-19 crisis, the ADP received government funding to build capacity and prepare for new and re-emerging diseases. By starting research and development of the COVID-19 vaccine from upstream to downstream using egg production technology and has also begun to develop vaccines made from cell cultures
The signing of the agreement is to establish a partnership with SK Bioscience, a manufacturer of inactivated, cultured, tri- and quadrivalent seasonal influenza vaccines in the form of Ready to Fill Bulk vaccines. and transfer of technology for the packaging process for the production of finished vaccines (Drug Product) by the FDA in order to use the facility and support system. resources the most worthwhile As well as creating knowledge and expertise for personnel as well, SK Science will be a consultant and transfer technology in production processes and various knowledge bodies to the FDA to create international standards. Study the opportunity to establish a major pharmaceutical manufacturing plant in Thailand.
Korea reveals the reason for cooperation with Thailand
Mr. An Jae Yong said that the reason for choosing The GPO joins hands because Thailand and the GPO are ready. supported by the government believe that cooperation will happen well In the past, we had a good relationship with the Thai government through many channels. And vaccines are among the long list of previous collaborations. This collaboration will be successful in technology transfer. and place of production The PPP is regarded as the center of the region.
The FDA is ready to cooperate with Korea to produce other vaccines such as shingles prevention.
The reporter asked how long it would take to transfer the technology and when it would start using it. Dr. Mingkwan said that following signing, there will be an agreement on cooperation in terms of price. with a preliminary agreement already Next year should be the vaccine in the form of a ready-to-pack or packaged vaccine. which is the nature of the middle water Then it will enter Phase 2, which will transfer technology from upstream to downstream. It is expected to be no more than 2 years. The vaccines in the GPO pipeline include both the influenza vaccine and the GPO Vac COVID vaccine. This signing is considered a big step. Because South Korea has many other vaccine production issues that are expected to transfer technology, such as the shingles vaccine.
Revealing vaccines that Thailand can produce by itself
side Dr. Nakorn Premsri, director of the National Vaccine Institute Said that the vaccines that Thailand currently produces are 1. BCG vaccine or tuberculosis vaccine. Produced by Queen Saovabha Memorial Institute 2. Cell-free pertussis vaccine from Bionet Asia Company Limited and 3. JD vaccine once morest encephalitis. It is a technology transfer and packaging by Global Biotech Products Co., Ltd., a joint venture of the Government Agency. In addition, there is an influenza vaccine from the Ministry of Public Health. It is expected to be registered in 2023 and is regarding to cooperate with SK as well in the shingles vaccine section.
“Vaccines made from cell cultures are new technologies. It is hoped that from the beginning of the cooperation, it will be further developed for research and production of own vaccines from other cells. which is very important for dealing with a pandemic Because it makes it faster in production, ”said Dr. Nakorn.
Dr. Nakhon said that in the past, the Vaccine Institute has done a lot to build Thailand’s vaccine security, for example, building the potential of research and development of vaccine production in important platforms. by mRNA vaccine Support for funding teams of the Faculty of Medicine Chulalongkorn University Associated with Bionet Asia, Viral Vaccine supports NSTDA. Biotech, KMUTT. Siam Bioscience, Inactivated Vaccine Support the government and subunit protein vaccines Support Biya company. In addition, there is a team of standardized laboratory animals. There is a human research team. All are national teams that can work from now on forward. In maintaining and enhancing the potential as well as trying to find cooperation from foreign countries to jointly develop make Thailand act faster
“Supporting multiple platforms in vaccine production This gives the opportunity to produce vaccines by ourselves to cope with various diseases. because they do not know what the new disease outbreak is and do not know which platform will work well which COVID-19 might tell us one way But if encountering a new disease, it might be another form. like when there was no covid-19 People still don’t know regarding mRNA vaccines, viral vector vaccines. therefore preparing for the future And it’s a matter of investment. I hope that the government will support it because it is a matter that requires continuous investment, ”said Dr. Nakorn.
1688469979
#Thailand #joins #Korea #Production #influenza #vaccine #cell #cultures #Raise #potential #Government #Pharmaceutical #Organization #Hfocus.org
